Chapter 1. LIVE ATTENUATED VACCINES MARKET– Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. LIVE ATTENUATED VACCINES MARKET– Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-131 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. LIVE ATTENUATED VACCINES MARKET– Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. LIVE ATTENUATED VACCINES MARKET- Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. LIVE ATTENUATED VACCINES MARKET- Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. LIVE ATTENUATED VACCINES MARKET– By Product Type

6.1. Viral

6.2. Bacterial

Chapter 7. LIVE ATTENUATED VACCINES MARKET– By Development

7.1. Tissue Culture

7.2. Embryonated Eggs

7.3. Live Animals

Chapter 8. LIVE ATTENUATED VACCINES MARKET– By Indication

8.1. Measles

8.2. Rotavirus

8.3. Oral Polio

8.4. Tuberculosis

8.5. Yellow Fever

8.6. Others

Chapter 9. LIVE ATTENUATED VACCINES MARKET– By Mode of Administration

9.1. Oral

9.2. Injectable

9.3. Others

Chapter 10. LIVE ATTENUATED VACCINES MARKET– By Distribution Channel

10.1. Online Pharmacies

10.2. Retail Pharmacies

10.3. Hospital Pharmacies

Chapter 11. LIVE ATTENUATED VACCINES MARKET– By End-User

11.1. Specialty Clinics

11.2. Hospitals

11.3. Homecare

11.4. Others

Chapter 12. LIVE ATTENUATED VACCINES MARKET– By Region

12.1. North America

12.2. Europe

12.3. The Asia Pacific

12.4. Latin America

12.5. Middle-East and Africa

Chapter 13. LIVE ATTENUATED VACCINES MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

13.1. Company 1

13.2. Company 2

13.3. Company 3

13.4. Company 4

13.5. Company 5

13.6. Company 6

13.7. Company 7

13.8. Company 8

13.9. Company 9

13.10. Company 10